The clinical significance of isocitrate dehydrogenase 1 (IDH1) point mutation in gliomas was first reported in 2008, the overall survival (OS) of glioblastoma patients with IDH1-mutated glioblastoma was demonstrated to be significantly longer than that of patients with wild-type IDH1 glioblastoma [2]. Here, IDH1 is linked to central nervous system cancer.